Skip to main content
SpringerLink
Log in

Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp6, des-Gly-NH2 10]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience

  • Chapter
Book cover Molecular Biology of Brain and Endocrine Peptidergic Systems

Part of the book series: Biochemical Endocrinology ((BIOEND))

  • 39 Accesses

Abstract

Man is unique among species in having adrenals which secrete large amounts of precursor steroids which are converted into active androgens in the prostate and other peripheral tissues (Acevedo and Goldzieher, 1965; Harper et al., 1974; Cameron et al., 1966; Voigt and Bartsch, 1986).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Acevedo, H.F., and Goldzieher, J.W., 1965, Further studies on the metabolism of 4-[4–14C]androstene-3,17-dione by normal and pathological human prostate tissue. Biochim. Biophys. Acta, 97:564.

    Google Scholar 

  • Bartsch, W., Knabbe, M., and Voigt, K.D., 1983, Regulation and compart-mentalization of androgens in rat prostate and muscle. J. Steroid Biochem., 19:929.

    Article  PubMed  CAS  Google Scholar 

  • Baulieu, E.E., 1963, Studies on the secretion and interconversion of the androgens. Rec. Progr. Horm. Res., 19:306.

    Google Scholar 

  • Bélanger, A., Dupont, A., and Labrie, F. 1984, Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422.

    Google Scholar 

  • Brendler, H., 1959, Current Cancer Concepts: therapy with orchiectomy or estrogens or both. JAMA, 210:1074.

    Article  Google Scholar 

  • Cameron, E.H., Baillie, A.H., Grant, J.K., Milne, J.A., and Thomson, J., 1966, Transformation in vitro of [7α -3H]dehydroepiandrosterone to [3H]testosterone by skin from men. Proc. of the Society for Endocrinology, J. Endocrinol. 35:xix.

    Google Scholar 

  • Cupps, R.E., Utz, D.C., Fleming, T.R., Carson, C.C., Bastable, J.R.G., Glashan, R.W., Bouffioux, C., Lardennois, B., Williams, R.E., De Pauw, M., and Sylvester, R., 1980, Definitive radiation therapy for prostatic carcinoma: Mayo Clinic Experience. J. Urol., 124:855.

    Google Scholar 

  • Drouin, J., and Labrie, F., 1976, Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology, 98:1528.

    Article  PubMed  CAS  Google Scholar 

  • Gibbons, R.P., Mason, J.T., Correa, R.A. Jr., Cummings, K.B., Taylor, W.J., Hafermann, M.D., and Richardson, R.D., 1979, Carcinoma of the prostate: local control with external beam radiation therapy. J. Urol., 121:310.

    PubMed  CAS  Google Scholar 

  • Glashan, R.W., and Robinson, M.R.G., 1981, Cardiovascular complications in the treatment of prostatic carcinoma. Brit. J. Urol., 53:624.

    Google Scholar 

  • Harper, M.E., Pike, A., Peeling, W.B., and Griffiths, K., 1974, Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J. Endocrinol., 60:117.

    Article  PubMed  CAS  Google Scholar 

  • Huggins, C., and Hodges, C.V., 1941, Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1:293.

    Google Scholar 

  • Johansson, J.E., Andersson, S.O., Beckman, K.W., Lingardh, G., and Zador, G., 1987, Clinical evaluation of Flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Urology, 29:55.

    Article  PubMed  CAS  Google Scholar 

  • Johnson, D.E., Scott, W.W., Gibbons, R.P., Prout, G.R., Schmidt, J.D., Chu, T.M., Gaeta, J., Sarott, J., and Murphy, G.P., 1977, National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report. Cancer Treat. Rep., 61:317.

    Google Scholar 

  • Jordan, W.P. Jr., Blackard, C.E., and Byar, D.P., 1977, Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med. J.. 70:1411.

    Google Scholar 

  • Kaplan, E.L., and Meier, P., 1958, Non parametric estimation from incomplete observation. Amer. Statist. Assoc. J., 457.

    Google Scholar 

  • Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F., 1987, Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer. J. Ster. Biochem., 28: 379–384.

    Google Scholar 

  • Labrie, F., Auclair, C., Cusan, L., Kelly, P.A., Pelletier, G., and Ferland, L., 1978, Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. in: “Endocrine approach to Male Contraception”, Int. J. Androl, V. Hansson, ed., (suppl 2), p. 303.

    Google Scholar 

  • Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P.A., Lefebvre, F.A., Lemay, A., and Raynaud, J.P., 1980, Antifertility effects of LHRH agonists in the male. J. Androl., 1:209.

    CAS  Google Scholar 

  • Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourcière, Y., Monfette, G., Laberge, J.G., Emond, J.P., Fazekas, A.T.A., Raynaud, J.P. and Husson, J.M., 1982, New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med., 5:267.

    Google Scholar 

  • Labrie, F., Dupont, A., and Bélanger, A., 1985a, A Complete androgen blockade for the treatment of prostate cancer, in: “Important Advances in Oncology”, V.T. De Vita, S. Hellman and S.A. Rosenberg, eds., J.B. Lippincott, Philadelphia.

    Google Scholar 

  • Labrie, F., Dupont, A., Bélanger, A., Lachance, R., and Giguère, M., 1985b, Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Brit. Med. J., 292:369.

    Google Scholar 

  • Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., and Bergeron, V., 1985c, Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Ster. Biochem., 23:833.

    Google Scholar 

  • Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., and Monfette, G., 1986, Treatment of prostate cancer with gonadotropin-releasing hormone agonists, Endocr Rev., 7:67.

    Article  PubMed  CAS  Google Scholar 

  • Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., and A. Dupont, 1987a, New Concepts on the androgen sensitivity of prostate cancer, in: “Progress in Clinical and Biological Research”, Prostate Cancer, Part A: Research, Endocrine Treatment and Histopatholo-gy, G.P. Murphy, S. Khoury, C. Kuss, R. Châtelain and L. Denis, eds., vol. 243A, pp. 145–172.

    Google Scholar 

  • Labrie, F., Dupont, A., and Bélanger, A., 1987b, LHRH agonists and antiandrogens in prostate cancer, in: “Genitourinary Cancer”, T.L. Ratliff and W.J. Catalona, eds., pp. 157–200, Martinus Nijhoff Publishers, Boston.

    Chapter  Google Scholar 

  • Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., and Bergeron, N., 1988, Benefits of combination therapy with Flutamide in patients relapsing after castration. Brit. J. Urol., 61:(in press).

    Google Scholar 

  • Labrie, F., and Veilleux, R., 1986, A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. The Prostate. 8:293.

    Article  PubMed  CAS  Google Scholar 

  • Luthy, I., and Labrie, F., 1987, Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. The Prostate, 10:89.

    Article  PubMed  CAS  Google Scholar 

  • Mettlin, C., Natarajan, N., and Murphy, G.P., 1982, Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int. Adv. Surg. Oncol., 5:277.

    Google Scholar 

  • Mobbs, B.G., Johnson, I.E., Connolly, J.G., and Thompson, J., 1983, Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J. Steroid Biochem., 19:1279.

    Article  PubMed  CAS  Google Scholar 

  • Moguilewsky, M., Fiet, J., Tournemine, C., and Raynaud, J. P., 1986, Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cáncer. J. Steroid Biochem., 24:139.

    Google Scholar 

  • Moore, R.J., Gazak, J.M. and Wilson, R., 1984, Regulation of cytopolasmic dihydrotestosterone binding in dog prostate by 17ß-estradiol. J. Clin. Invest., 60:351.

    Google Scholar 

  • Murphy, G.P., Beckley, S., Brady, M.F., Chu, M., Dekernion, J.B., Dhabuwala, C., Gaeta, J.F., Gibbons, R.P., Loening, S.A., McKiel, C.F., McLeod, D.G., Pontes, J.E., Prout, G.R., Scardino, P.T., Schlegel, J.U., Schmidt, J.D., Scott, W.W., Slack, N.H., and Soloway, M., 1983, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormone alone. Cancer, 51:1264.

    Article  PubMed  CAS  Google Scholar 

  • Nesbit, R.M., and Baum, W.C., 1950, Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA, 143:1317.

    Article  CAS  Google Scholar 

  • Ojasso, T., 1987, Nilutamide. Drugs of the Future, 12:763.

    Google Scholar 

  • Paulson, D.F., 1984, Treatment of locally confined prostatic cancer: radiotherapy versus surgery-limits of curability, in: “Progress and controversies in Oncological Urology”, K.I.H. Kurth, F.M.J. Debryene, F.H. Schraeder, T.A.W. Splinter and T.D.J. Wagener, eds, p. 482. Alan R. Liss Inc., New York.

    Google Scholar 

  • Pavone-Macaluso, M., De Voogt, H.J., Viggiano, G., Baqrasolo, E., Lardennois, B., De Pauw, M. and Sylvester, R., 1986, Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol., 136:624

    PubMed  CAS  Google Scholar 

  • Poyet, P., Labrie, F., 1985, Comparison of the antiandrogenic/androgenic activities of Flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42: 283–288.

    Google Scholar 

  • Priore, R., 1984, Prognostic factors in NPCP protocols, in: “National Prostatic Cancer Project, Treatment Subgroup Meeting”, Minutes, New Orleans.

    Google Scholar 

  • Sanford, E.J., Paulson, D.F., Rohner, T.J., Drago, J.R., Santen, R.G., and Bardin, C.W., 1977, The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J. Urol., 118:1019.

    PubMed  CAS  Google Scholar 

  • Simard, J., Luthy, I., Guay, J., Bélanger, A. and Labrie, F., 1986, Characteristics of interaction of the antiandrogen flutamide with the androgenr eceptor in various target tissues. Mol. Cell. Endocrinol., 44:261.

    Google Scholar 

  • Slack, N.H., Brady, M.F., Murphy, G.P (1984). Investigators in the National Prostatic Cancer Project Stable versus partial response in advanced prostate cancer, The Prostate, 4:401.

    Article  Google Scholar 

  • Smith, J.A., Glode, L.M., Wettlaufer, J.N., Stein, B.S., Glass, A.G., Max, T.D., Anbar, D., Jagst, C.L. and Murphy, G.P., 1985, Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of the prostate, Urology, 20:106.

    Article  Google Scholar 

  • Smith, Ph.D., Suciu, S., Robinson, M.R.G., Richards, B., Bastable, J.R.G., Glashan, R.W., Bouffioux, G., Lardennois, B., Williams, R.E., De Pauw, M. and Sylverter, R., 1986, A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J. Urol., 136:619.

    PubMed  CAS  Google Scholar 

  • Sogani, P.C., Ray, B. and Whitmore, W.F. Jr., 1975, Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology, 6:164.

    Article  PubMed  CAS  Google Scholar 

  • The Leuprolide Study Group, 1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl. J. Med., 311:1281.

    Article  Google Scholar 

  • Tomlinson, R.L., Currie, D.P. and Boyce, W.H., 1977, Radical prostatectomy: palliation for stage C carcinoma of the prostate. J. Urol., 117:85.

    PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Urological Research Group, 1967, Carcinoma of the prostate: treatment comparisons. J. Urol. 98: 516.

    Google Scholar 

  • Voigt K.D, Bartsch W., 1986, Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J. Steroid Biochem., 25:749.

    Article  PubMed  CAS  Google Scholar 

  • Whitmore, W.F. Jr., 1973, The natural history of prostatic cancer. Cancer, 32:1104.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Molecular Endocrinology, Medicine, Nuclear Medicine and Urology, Laval University Medical Center, Québec, G1V 4G2, Canada

    Fernand Labrie, André Dupont, Alain Bélanger, Jacques Simard, Claude Labrie, Richard Poulin, Isabel Luthy, Daniel Lacoste, Bianca Marchetti, Lionel Cusan, Gilles Manhès, Gérard Monfette & Jean Emond

Authors
  1. Fernand Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Dupont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alain Bélanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacques Simard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claude Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Poulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isabel Luthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Raymonde Veilleux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel Lacoste
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bianca Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lionel Cusan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gilles Manhès
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Gérard Monfette
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jean Emond
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinical Research Institute, Montreal, Quebec, Canada

    Michel Chrétien

  2. International Foundation for Biochemical Endocrinology, Blue Hill Falls, Maine, USA

    Kenneth W. McKerns

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Plenum Press, New York

About this chapter

Cite this chapter

Labrie, F. et al. (1988). Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp6, des-Gly-NH2 10]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience. In: Chrétien, M., McKerns, K.W. (eds) Molecular Biology of Brain and Endocrine Peptidergic Systems. Biochemical Endocrinology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8801-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-8801-2_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-8803-6

  • Online ISBN: 978-1-4684-8801-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation